Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma
Nondecreased muscle volume after initiating AB therapy was associated with improved treatment efficacy and prognosis in patients with u-HCC.
Authors
- Hideko Ohama (ORCID: https://orcid.org/0000-0002-1882-824X)
- Joji Tani (ORCID: https://orcid.org/0000-0001-8801-2505)
- Hironori Tanaka (ORCID: https://orcid.org/0000-0003-4712-0192)
- Akio Moriya (ORCID: https://orcid.org/0000-0002-3380-6460)
- Tetsu Tomonari (ORCID: https://orcid.org/0000-0002-8484-9866)
- Atsushi Hiraoka (ORCID: https://orcid.org/0000-0003-1989-0480)
- Yoshiko Nakamura
- Masashi Hirooka (ORCID: https://orcid.org/0000-0001-5634-5313)
- Takaaki Tanaka (ORCID: https://orcid.org/0000-0001-8264-9468)
- Chikara Ogawa (ORCID: https://orcid.org/0000-0002-4534-6692)
- Hironori Ochi
- Fujimasa Tada (ORCID: https://orcid.org/0009-0007-3964-5876)
- Asahiro Morishita (ORCID: https://orcid.org/0000-0002-0760-3045)
- Yusuke Imai (ORCID: https://orcid.org/0000-0003-4133-8481)
- Akihiro Deguchi
- Akira Hirose
Institutions
- Kagawa University (JP)
- Takamatsu Red Cross Hospital (JP)
- Mito Saiseikai General Hospital (JP)
- Matsuyama Red Cross Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- Ehime University (JP)
- Kōchi University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1111/hepr.14201
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32